热门资讯> 正文

Abivax报告财年业绩

2026-03-24 04:16

阿斯利康(AZN) 0
礼来制药(LLY) 0

Abivax press release (ABVX): FY
The Company had cash, cash equivalents, and short-term investments of €530.4 million as of December 31, 2025, providing a projected cash runway into Q4 2027 based on current operating assumptions.
Research and development (“R&D”) expenses increased by €31.2 million to €177.8 million (70.9% of operating expenses) in 2025 compared to €146.5 million (79.0% of operating expenses) in 2024.

More on Abivax

Abivax: Maintaining 'Strong Buy' On Buyout Speculation And Obefazimod Advancement
Abivax: Don't Just Buy The Rumor, Buy The Fundamentals
Abivax pares gain after denying AstraZeneca speculation
Abivax CEO responds to Lilly acquisition rumors
Seeking Alpha’s Quant Rating on Abivax

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。